CaMKII binding domain self-assembled protein nanoparticles and preparation and application thereof

Self-assembly of protein nanoparticles by CaMKII binding domain, the existing anti-tumor immune adjuvant has solved the problems of high toxicity and weak immune enhancement effect, and has achieved the promotion and maturation of macrophages and dendritic cells, and enhanced the anti-tumor immune response. , improve the effect of tumor immunotherapy.

CN119060980APending Publication Date: 2024-12-03NANJING UNIV OF POSTS & TELECOMM
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411233554.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

现有的抗肿瘤免疫佐剂存在毒性高、免疫增强效果弱的问题,难以有效激活巨噬细胞和树突状细胞以增强抗肿瘤免疫反应。

Method used

Protein nanoparticles self-assembled by CaMKII binding domain, self-assembled and formed in buffer by recombinant protein monomers, and are used to prepare adjuvants or anti-tumor drugs that enhance tumor immunotherapy, promote macrophage polarization and dendritic cell maturation , thereby enhancing the immune response.

Benefits of technology

It significantly promotes the proliferation and maturation of macrophages and dendritic cells, enhances their antigen presentation ability and release of inflammatory cytokines, selectively improves the anti-tumor immune response, and enhances the efficacy of tumor immunotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060980A_ABST
    Figure CN119060980A_ABST
Patent Text Reader

Abstract

The invention discloses CaMKII binding domain self-assembled protein nanoparticles as well as a preparation method and application of the CaMKII binding domain self-assembled protein nanoparticles. The CaMKII binding domain self-assembled protein nanoparticles are formed by self-assembling a recombinant protein monomer in a buffer solution, and the amino acid sequence of the recombinant protein monomer at least comprises a sequence as shown in SEQ ID NO.1. The recombinant protein monomer is obtained through recombinant expression by means of molecular biology. According to the present invention, the proliferation of macrophages and dendritic cells can be selectively promoted, the proliferation of fibroblasts and tumor cells cannot be promoted, the polarization of the macrophages to the M1 phenotype is promoted, the antigen presentation ability of the macrophages is enhanced, a large amount of inflammatory cytokines TNF-alpha and IL-6 are released, the maturation of the dendritic cells is promoted, and the antigen presentation ability of the dendritic cells is enhanced; the adjuvant provided by the invention has a good application prospect, can be applied to vaccine synergy and immunotherapy matched with the existing anti-tumor medicine, and effectively improves the efficacy of the existing anti-tumor therapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a protein nanoparticle and preparation and application thereof, in particular to a CaMKII binding domain self-assembly protein nanoparticle and preparation and application thereof. Background Art

[0002] Anti-tumor immunotherapy generally involves the activation of macrophages and dendritic cells. Macrophages are phagocytic cells that participate in nonspecific defense (innate immunity) and specific defense (cellular immunity) in vertebrates. Their main function is to phagocytose and digest cell debris and pathogens in the form of fixed cells or free cells, and activate lymphocytes or other immune cells to respond to pathogens. Macrophages are immune cells with multiple functions and are important objects for studying cellular phagocytosis, cellular immunity and molecular immunology. It is generally believed that macrophages are stimulated into M1 phenotype and M2 phenotype under different environmental influences. In the tumor microenvironment, macrophages mostly show an immunosuppressive M2 phenotype. Under the stimulation of agonists or immune adjuvants, macrophages in the tumor microenvironment are expected to polarize into the M1 phenotype that is beneficial to tumor treatment, release inflammatory cytokines, enhance antigen presentation and phagocytic ability, and thus curb tumor growth. Dendritic cells (DC) are the most powerful professional antigen-presenting cells in the body. They can efficiently ingest, process and present antigens. Immature DCs have strong migration ability, and mature DCs can effectively activate naive T cells. They are at the center of initiating, regulating, and maintaining immune responses. Most DCs in the human body are in an immature state, expressing low levels of co-stimulatory factors and adhesion factors. Their ability to stimulate the proliferation of allogeneic mixed lymphocytes in vitro is low, but immature DCs have extremely strong antigen phagocytosis ability. When they ingest antigens (including in vitro processing) or are stimulated by certain factors, they differentiate into mature DCs, and mature DCs express high levels of co-stimulatory factors and adhesion factors. During the maturation process, DCs migrate from peripheral tissues that come into contact with antigens into secondary lymphoid organs, come into contact with T cells and stimulate immune responses.

[0003] Immune adjuvants are referred to as adjuvants, or non-specific immunoproliferative agents, which refer to auxiliary substances that can enhance the body's immune response to antigens or change the type of immune response when injected into the body together with antigens or in advance. The development of immune adjuvants is of great significance in the fields of antiviral vaccines and tumor immunotherapy. Viral vaccine adjuvants refer to non-specific immune enhancing substances that are injected into the body in advance or at the same time as viral antigens to enhance the body's immune response to viral antigens or change the type of immune response. They can enhance the body's immune response to antigens, but have disadvantages such as local inflammatory response, weak immunogenicity, short half-life, weak targeting, slow absorption, and high storage and transportation requirements. Mainstream tumor treatment methods, such as chemotherapy and radiotherapy, have large toxic side effects, and immunotherapy based on immune checkpoint inhibitors is also subject to the constraints of immune tolerance. Immune adjuvants can be used in combination with a variety of therapies to improve the effects of chemotherapy, radiotherapy and immunotherapy, enhance the body's immune response, and prolong the survival of cancer patients. At present, there are only a handful of immune adjuvants used in tumor immunotherapy, and there is an urgent need to develop anti-tumor immune adjuvants with low toxicity and strong immune enhancement effects.

[0004] Calcium / calmodulin-dependent protein kinase II (CaMKII) consists of four domains: the catalytic domain, the inhibitory domain, the Ca 2+ / CaM (Camodulin, calmodulin) domain and binding domain. Existing research mainly focuses on the biological function of the whole CaMKII protein, and the biological function research of independent domains of CaMKII, especially the effect of a certain independent domain of CaMKII on anti-tumor immunity, has not been reported. Summary of the invention

[0005] Purpose of the invention: The purpose of the present invention is to provide a CaMKII binding domain self-assembled protein nanoparticle to solve the problem of how to specifically enhance the immune response. Another purpose of the present invention is to propose a method for preparing CaMKII binding domain self-assembled protein nanoparticles to solve the problem of how to prepare CaMKII binding domain self-assembled protein nanoparticles. The third purpose of the present invention is to propose the use of CaMKII binding domain self-assembled protein nanoparticles in the preparation of adjuvants or anti-tumor drugs that enhance tumor immunotherapy to solve the problem of how to improve the efficacy of anti-tumor drugs.

[0006] Technical solution: The CaMKII binding domain self-assembling protein nanoparticles described in the present invention are formed by self-assembly of recombinant protein monomers in a buffer solution, and the amino acid sequence of the recombinant protein monomers at least includes the sequence shown in SEQ ID NO.1.

[0007] Preferably, the amino acid sequence of the recombinant protein monomer is as shown in SEQ ID NO.1.

[0008] Preferably, the protein nanoparticles are 2-12mers of recombinant protein monomers, and the buffer is a neutral Tris buffer, more specifically, a Tris buffer with a pH of 7.5 to 8.5.

[0009] In order to obtain the above-mentioned CaMKII binding domain self-assembled protein nanoparticles, the present invention provides a method for preparing the protein nanoparticles, characterized in that it comprises the following steps:

[0010] (1) constructing an expression vector containing a recombinant protein monomer gene;

[0011] (2) transforming the expression vector into engineered bacteria to construct recombinant bacteria;

[0012] (3) Cultivating recombinant bacteria to express recombinant protein monomers;

[0013] (4) After the culture is completed, the bacteria are collected, broken into pieces, and then the protein is purified to obtain protein nanoparticles.

[0014] Preferably, in step (1), the recombinant protein monomer gene sequence is as shown in SEQ ID NO.2; the expression vector is a recombinant plasmid, in some embodiments, the blank plasmid is pET-29b(+), and the multiple cloning site for inserting the recombinant protein monomer gene into the blank plasmid is Ndel / Xhol. The recombinant protein monomer gene sequence can be designed with SEQ ID NO.2 as the target sequence, and the recombinant protein monomer gene can be obtained by conventional PCR reaction.

[0015] Preferably, in step (2), the transformation method is: after mixing the expression vector solution with the engineered bacterial suspension, ice-bath for 2-8 minutes, then treat at 41-43°C for 25-35 seconds, ice-bath for 1.5-2.5 minutes, and then apply the bacterial solution to the surface of a solid culture medium containing antibiotics. After culturing, a positive single colony is picked as the recombinant bacteria. The engineered bacteria in the present invention can be Escherichia coli, such as BL-21, or can be yeast, lactic acid bacteria or Bacillus subtilis. The antibiotic can be kanamycin, ampicillin, chloramphenicol, etc. The specific type of antibiotic can be selected according to the resistance gene of the expression vector.

[0016] Preferably, in step (3), the method for culturing the recombinant bacteria is: inoculating the recombinant bacteria into LB liquid culture medium, and culturing the bacteria at 37° C. for 12-26 hours, during which time, inducing expression at 2-6 hours.

[0017] Preferably, in step (4), the method of purifying the protein after disrupting the bacteria is: resuspending the bacteria and then disrupting the bacteria, collecting the supernatant by centrifugation, and purifying the supernatant using a nickel column and a chromatography column, wherein both the resuspending of the bacteria and the chromatography column purification use a neutral Tris buffer.

[0018] The bacterial cells can be broken by ultrasonic disruption, and the conditions for ultrasonic disruption are an ultrasonic disruptor, an ultrasonic power of 80%, an ultrasonic interval of 10 seconds and an interval of 10 seconds, and a total ultrasonic time of 5 minutes.

[0019] The protein purification method may also include affinity chromatography, ion exchange chromatography, gel filtration, and the like.

[0020] The conditions for the chromatography column purification are: the chromatography column is selected as Superdex TM 200Increase 10 / 300GL, flow rate is 0.6mL / min, collection column volume is about 12mL, and the highest peak is collected as standard.

[0021] In some embodiments, the Tris buffer used in bacterial cell disruption and protein purification is a solution of 20 mM Tris [pH 8.0], 100 mM NaCl.

[0022] The present invention further applies the above-mentioned CaMKII binding domain self-assembling protein nanoparticles to the preparation of adjuvants or anti-tumor drugs for enhancing tumor immunotherapy. The present invention can selectively enhance the proliferation capacity of macrophages and dendritic cells, promote the polarization of macrophages into the M1 phenotype that is beneficial to tumor treatment, and promote the maturation of dendritic cells, thereby presenting antigens and activating T cells, thereby achieving anti-tumor effects.

[0023] Preferably, the tumor includes one or more of melanoma, breast cancer, cervical cancer, colorectal cancer, gastric cancer, lung cancer, liver cancer, esophageal cancer, pancreatic cancer, brain cancer, blood cancer, lymphoma, and bile duct cancer.

[0024] The anti-tumor drug comprises CaMKII binding domain self-assembled protein nanoparticles and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier comprises excipients, disintegrants, adhesives, lubricants, antioxidants, coating agents, colorants, fragrances, surfactants, etc., and the dosage form of the anti-tumor drug comprises granules, capsules, tablets, injections, infusions, suppositories, etc.

[0025] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages: 1. The present invention can selectively promote the proliferation of macrophages and dendritic cells, but cannot promote the proliferation of fibroblasts and melanoma cells, while promoting the polarization of macrophages to the M1 phenotype and enhancing their antigen presenting ability, promoting macrophages to release a large amount of inflammatory cytokines TNF-α and IL-6, and can promote the maturation of dendritic cells, successfully achieving the purpose of enhancing tumor immunotherapy; 2. The present invention provides a class of adjuvants with good application prospects, which can be used to enhance vaccine efficacy, enhance the effect of tumor immunotherapy, and improve the efficacy of existing anti-tumor methods. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 This is the SDS-PAGE result of the nickel column elution product;

[0027] Figure 2 It is the SEC curve of the protein purification instrument of the recombinant protein;

[0028] Figure 3 DLS data of recombinant protein in buffer solution;

[0029] Figure 4 The effect of 10 μM protein nanoparticles on the proliferation activity of macrophage RAW264.7;

[0030] Figure 5 The effect of 10 μM protein nanoparticles on the proliferation activity of bone marrow-derived dendritic cells (BMDCs);

[0031] Figure 6 The effect of 10 μM protein nanoparticles on the proliferation activity of melanoma cells B16-OVA;

[0032] Figure 7 The effect of 10 μM protein nanoparticles on the proliferation activity of fibroblast 3T3;

[0033] Figure 8 The effect of 10 μM protein nanoparticles on the release of inflammatory cytokines TNF-α and IL-6 after stimulation of macrophages RAW264.7;

[0034] Fig. 9 The effect of 10 μM protein nanoparticles on the expression of CD86 and MHC-II after stimulation of macrophages RAW264.7;

[0035] Fig.10 The effect of 10 μM protein nanoparticles on the expression of CD80 and CD86 in mouse bone marrow-derived dendritic cells BMDCs; DETAILED DESCRIPTION

[0036] The technical solution of the present invention is further described below in conjunction with the accompanying drawings.

[0037] In the present invention, the plasmid is provided by Sangon Biotech (Shanghai) Co., Ltd., the mouse macrophage cell line RAW264.7, the mouse fibroblast cell line 3T3, the melanoma cell line B16-OVA and the CCK8 detection kit are purchased from Jiangsu Keygen Biotech Co., Ltd., the TNF-α and IL-6 cytokine ELISA detection kits are purchased from Suzhou Sizhengbai Biotechnology Co., Ltd., the CD80, CD86, and MHC-II flow cytometry antibodies are purchased from Dakoway Biotechnology Co., Ltd., the bone marrow-derived dendritic cells BMDCs are extracted from fresh cells of mouse bone marrow, and the gene sequence shown in SEQ ID NO.2 and the primers required for its amplification are synthesized by a biological company.

[0038] Example 1: A CaMKII binding domain protein self-assembling nanoparticle, which is a dodecamer formed by self-assembly of a recombinant protein monomer having an amino acid sequence as shown in SEQ ID NO. 1. The amino acid sequence of the recombinant protein monomer is as follows:

[0039] GSSHHHHHHSSGENLYFQGSTTIEDEDTKVRKQEIIKVTEQLIEAISNGDFESYTK MCDPGMTAFEPEALGNLVEGLDFHRFYFENLWSRNSKPVHTTILNPHIHLMGDESACI AYIRITQYLDAGGIPRTAQSEETRVWHRRDGKWQIVHFHRSGAPSVLPH.

[0040] The preparation method of the above protein self-assembled nanoparticles is as follows:

[0041] (1) In this embodiment, the recombinant protein monomer gene sequence is shown in SEQ ID NO.2 and is synthesized by a biological company. Ndel / Xhol restriction sites are added at both ends of the sequence to facilitate connection to the expression vector. The synthesized gene sequence is connected to the vector: pET-29b(+) plasmid is selected as a blank vector, and the pET-29b(+) plasmid and the recombinant protein monomer gene are double-digested with Ndel / Xhol and then enzyme-linked to obtain a recombinant plasmid. After sequencing verification, a recombinant expression vector containing the recombinant protein monomer gene is obtained.

[0042] (2) The recombinant expression vector is transformed into the engineered bacteria to construct the recombinant bacteria. The method is as follows: the recombinant expression vector solution is mixed with the BL-21 engineered bacteria suspension and then placed in an ice-water bath for 5 minutes. The mixture is then treated at 42°C for 30 seconds and then placed in an ice-water bath for 2 minutes. The bacterial solution is then spread on the surface of a solid culture medium containing kanamycin. After cultivation, a positive single colony is picked out, which is the recombinant bacteria.

[0043] (3) The recombinant bacteria were inoculated into LB liquid culture medium and cultured at 37°C for 16 h. During this period, the expression of the recombinant protein monomer was induced at 2-6 h.

[0044] (4) After the culture is completed, the bacterial precipitate is collected by centrifugation at 5000r / min for 15min, and the collected bacterial precipitate is resuspended in a buffer to obtain a bacterial suspension. The bacterial suspension is treated with an integrated ultrasonic disruptor, with an ultrasonic power of 80%, an ultrasonic interval of 10s for 10s, and a total ultrasonic time of 5min. After the bacterial cells are disrupted, the supernatant is collected by centrifugation at 13000r / min for 30min. The supernatant is crudely purified by a nickel column and then purified by a protein purifier (the chromatography column is Superdex TM 200Increase 10 / 300GL, flow rate 0.6mL / min), collect the highest peak of about 12mL column volume, and obtain protein nanoparticles (hereinafter referred to as CaMKII) solution. The buffer used in bacterial cell disruption and protein purification instrument purification process is 20mM Tris [pH 8.0], 100mM NaCl Tris buffer.

[0045] The results of protein purification process are as follows Figure 1 , Figure 2 and Figure 3 As shown, Figure 1 The SDS-PAGE test result of the nickel column elution product is shown in the figure. The first column is the marker and the second column is the elution product. The buffer solution prepared with the formula of 20mM Tris [pH 8.0] and 100mM NaCl is used to dilute the test substance. The 4%-12% SDS-PAGE is run to verify whether the monomer molecular weight of the elution product is equivalent to the theoretical value. Figure 1 The results showed that the monomer band of the eluted product appeared between the molecular weight of 15kDa-30kDa marker and was slightly higher than 15kDa, which was equivalent to the theoretical molecular weight of the CaMKII binding domain monomer of 18.5kDa.

[0046] Figure 2 The SEC test data shows that the highest peak column volume of the SEC curve is about 12.3 mL, which corresponds to the molecular weight of the recombinant protein monomer dodecamer, indicating that the recombinant protein monomer can self-assemble to form dodecamers in the buffer. Collect the purified CaMKII solution, concentrate it, and store it at 4°C for a short term (if it needs to be stored at -80°C for a long term).

[0047] Figure 3 For DLS detection data, a buffer solution with a formula of 20 mM Tris [pH 8.0] and 100 mM NaCl was prepared to dilute the CaMKII solution, and the protein particle size was obtained by DLS detection. Figure 3The results showed that the average particle size of the detected CaMKII was 11.4 nm, proving that CaMKII can stably exist in the buffer solution of this formula.

[0048] Example 2: In order to confirm the immune enhancement effect of CaMKII prepared in Example 1, the following experiment was performed:

[0049] Experiment 1: CCK-8 (Cell Counting Kit-8) was used to determine the effect of 10 μM concentration of CaMKII prepared in Example 1 on the proliferation of macrophage RAW264.7. The specific implementation scheme is as follows:

[0050] (1) Take RAW264.7 cells with good growth status and prepare a cell suspension. Adjust the final cell concentration to 5×10 4 100 μL of cell suspension was added to each well of a 96-well plate and cultured in a 37°C and 5% CO2 incubator until adherence.

[0051] (2) The CaMKII concentration was set to 10 μM, and 6 replicate wells were set for each group, and a control group was set up at the same time. After adding the drug and incubating in a 37°C and 5% CO2 incubator for 24 hours, the supernatant was discarded, and 100 μL of fresh DMEM (Dulbecco's Modified Eagle Medium) culture medium and 10 μL of CCK-8 solution were added to each well, and the culture was continued for 2 hours. The 96-well plate was placed on a microplate reader and the absorbance of each well was measured at 450 nm.

[0052] The cell proliferation rate was calculated according to the following formula:

[0053] Cell proliferation rate (%) = [(OD value of sample well - OD value of normal well) / OD value of normal well] × 100%.

[0054] Figure 4 The results of the CCK-8 experiment are shown in Figure 3, where *** is the result of the t-test, indicating a significant difference from the control group. It can be seen that CaMKII at a concentration of 10 μM has no toxicity to macrophages RAW264.7 and has the effect of promoting macrophage proliferation.

[0055] Experiment 2: CCK-8 (Cell Counting Kit-8) was used to determine the effect of 10 μM concentration of CaMKII prepared in Example 1 on the proliferation of bone marrow-derived dendritic cells BMDCs. The specific implementation scheme is as follows:

[0056] (1) Fresh cells extracted from mouse bone marrow were used as raw materials. They were treated with red blood cell lysis buffer for 2 minutes, centrifuged to remove the supernatant, and resuspended in culture medium to adjust the final cell concentration to 5×10 4100 μL of cell suspension was added to each well of a 96-well plate and the plate was cultured in a 37°C and 5% CO2 incubator.

[0057] (2) The CaMKII concentration was set to 10 μM, and 6 replicate wells were set for each group, and a control group was set up at the same time. After adding the drug and incubating in a 37°C and 5% CO2 incubator for 24 h, 10 μL of CCK-8 solution was added to each well, and the culture was continued for 2 h. The 96-well plate was placed on a microplate reader and the absorbance of each well was measured at 450 nm.

[0058] The cell proliferation rate was calculated according to the following formula:

[0059] Cell proliferation rate (%) = [(OD value of sample well - OD value of normal well) / OD value of normal well] × 100%.

[0060] Figure 5 The results of the CCK-8 experiment are shown in Figure 4, where *** is the result of the t-test, indicating a significant difference from the control group. It can be seen that CaMKII at a concentration of 10 μM has no toxicity to bone marrow-derived dendritic cells BMDCs and greatly promotes their proliferation, indicating that CaMKII has the effect of promoting macrophage proliferation.

[0061] Experiment 3: CCK-8 (Cell Counting Kit-8) was used to test the effect of 10 μM concentration of heavy CaMKII prepared in Example 1 on the proliferation of melanoma cells B16-OVA. The specific implementation scheme is as follows:

[0062] (1) Take B16-OVA cells with good growth status and prepare a cell suspension. Adjust the final cell concentration to 5×10 4 100 μL of cell suspension was added to each well of a 96-well plate and cultured in a 37°C and 5% CO2 incubator until adherence.

[0063] (2) Set the CaMKII concentration to 10 μM, set 6 replicates in each group, and set a control group. Add the drug and incubate in a 37°C and 5% CO2 incubator for 24 h, discard the supernatant, add 100 μL of fresh DMEM medium and 10 μL of CCK-8 solution to each well, continue incubation for 2 h, and place the 96-well plate on an ELISA reader to measure the absorbance of each well at 450 nm.

[0064] The cell proliferation rate was calculated according to the following formula:

[0065] Cell proliferation rate (%) = [(OD value of sample well - OD value of normal well) / OD value of normal well] × 100%.

[0066] Figure 6The results of the CCK-8 experiment are shown in Figure 2, where ns is the result of the t-test, indicating that there is no significant difference with the control group. Figure 6 It can be seen that CaMKII at a concentration of 10 μM cannot promote the proliferation of melanoma cells B16-OVA, which indirectly confirms the selective proliferation effect of CaMKII on macrophages and dendritic cells.

[0067] Experiment 4: CCK-8 (Cell Counting Kit-8) was used to determine the effect of 10 μM concentration of CaMKII prepared in Example 1 on the proliferation of fibroblast 3T3. The specific implementation scheme is as follows:

[0068] (1) Take 3T3 cells in good growth state and prepare a cell suspension. Adjust the final cell concentration to 5×10 4 100 μL of cell suspension was added to each well of a 96-well plate and cultured in a 37°C and 5% CO2 incubator until adherence.

[0069] (2) The CaMKII concentration was set to 10 μM, and 6 replicate wells were set for each group, and a control group was set up at the same time. After adding the drug and incubating in a 37°C and 5% CO2 incubator for 24 h, the supernatant was discarded, 100 μL of fresh DMEM medium and 10 μL of CCK-8 solution were added to each well, and the culture was continued for 2 h. The 96-well plate was placed on a microplate reader and the absorbance of each well was measured at 450 nm.

[0070] The cell proliferation rate was calculated according to the following formula:

[0071] Cell proliferation rate (%) = [(OD value of sample well - OD value of normal well) / OD value of normal well] × 100%.

[0072] Figure 7 The results of the CCK-8 experiment are shown in Figure 2, where ns is the result of the t-test, indicating that there is no significant difference with the control group. It can be seen that CaMKII at a concentration of 10 μM has no toxicity to fibroblast 3T3 and cannot promote its proliferation, which indirectly confirms the selective proliferation effect of CaMKII on macrophages and dendritic cells.

[0073] Experiment 5: Determine the effect of CaMKII prepared in Example 1 at a concentration of 10 μM on the release of inflammatory cytokines TNF-α and IL-6 in RAW264.7. The specific implementation scheme is as follows:

[0074] (1) Take RAW264.7 cells with good growth status and prepare a cell suspension. Adjust the final cell concentration to 5×10 5 2000 μL of cell suspension was added to each well of a 6-well plate and the plate was incubated at 37°C and 5% CO2 until adherence.

[0075] (2) The concentration of CaMKII was set to 10 μM, and a control group was set up, with three parallel control groups in each group. After adding the drug and incubating in a 37°C and 5% CO2 incubator for 24 h, the supernatant was collected, and the levels of inflammatory cytokines TNF-α and IL-6 in the cell supernatant were detected using an ELISA kit, and the absorbance of each well was measured at 450 nm on an enzyme reader.

[0076] The cytokine content was calculated according to the following method:

[0077] The content (pg / mL) of TNF-α and IL-6 is calculated by the standard curve drawn by the standard test in the ELISA kit. For example, the standard curve y=a*x+b (a and b are constants), y is the OD 450 value measured by the microplate reader, and the x value calculated by y is the cytokine content.

[0078] Figure 8 The figure shows the results of the concentration detection of inflammatory cytokines TNF-α and IL-6, where *** is the result of the t-test, indicating a significant difference from the control group. It can be seen that CaMKII at a concentration of 10 μM can significantly promote the release of a large number of inflammatory cytokines TNF-α and IL-6 by macrophages RAW264.7, proving that CaMKII can promote the polarization of macrophages into the M1 phenotype.

[0079] Experiment 6: The effect of CaMKII prepared in Example 1 on the expression of CD86 (macrophage M1 phenotype marker) and MHC-II (antigen presentation marker) after stimulation of macrophage RAW264.7 was determined by flow cytometry. The specific implementation scheme is as follows:

[0080] (1) Take RAW264.7 cells with good growth status and prepare a cell suspension. Adjust the final cell concentration to 5×10 5 2000 μL of cell suspension was added to each well of a 6-well plate and the plate was incubated at 37°C and 5% CO2 until adherence.

[0081] (2) Set the CaMKII concentration to 10 μM, and set up a control group, with three parallel control groups in each group. Add the drug and incubate in a 37°C and 5% CO2 incubator for 24 hours. After incubation, resuspend the cells with the prepared buffer (500 μL fetal bovine serum FBS + 50 mL PBS), collect them in a 1.5 mL centrifuge tube, wash them twice with the buffer, add PE anti-mouse CD86, APC anti-mouse IA / IE, incubate in the dark for 30 minutes, add the prepared buffer, wash and centrifuge, and leave about 100 μL of cells for flow cytometry detection.

[0082] The experimental results are as follows Fig. 9 As shown, * is the result of t-test, indicating significant difference from the control group. Compared with the control group, 10 μM concentration of CaMKII effectively increased the expression of CD86 and MHC-II in macrophages RAW264.7, indicating that 10 μM concentration of CaMKII can polarize RAW264.7 to M1 phenotype and enhance its antigen presentation ability.

[0083] Experiment 7: Determine whether 10 μM CaMKII prepared in Example 1 promotes the maturation of bone marrow-derived dendritic cells BMDCs. The specific implementation scheme is as follows:

[0084] Fresh cells extracted from mouse bone marrow were used as raw materials. They were treated with red blood cell lysis buffer for 2 minutes, centrifuged to remove the supernatant, and resuspended in culture medium to adjust the final cell concentration to 5×10 5 / mL, add 2000μL cell suspension to each well of a 6-well plate, set the CaMKII concentration to 10μM, set a control group at the same time, and set three parallel control groups in each group. After adding the drug and incubating in a 37°C and 5% CO2 incubator for 24h, re-collect the cells, and use flow cytometry to analyze the expression of CD80 and CD86 (dendritic cell maturation markers). Analyze with FlowJo software to obtain the flow analysis data graph (the first quadrant represents CD80 and CD86 double positive), and draw a bar graph as follows.

[0085] The experimental results are as follows Fig.10 As shown, *** is the result of t-test, indicating significant difference from the control group. Compared with the control group, 10 μM CaMKII can significantly promote the simultaneous expression of CD80 and CD86 by dendritic cells (the flow cytometry analysis shows that the ratio in the first quadrant is higher than that of the control group), proving its effect in promoting the maturation of dendritic cells.

[0086] Combined with the above analysis results, it can be seen that the CaMKII binding domain at a concentration of 10μM can effectively activate macrophages, enhance macrophage viability, promote macrophage proliferation, and polarize macrophages to M1 phenotype, enhance macrophage antigen presentation ability, and release a large number of inflammatory cytokines TNF-α and IL-6. At the same time, the CaMKII binding domain at a concentration of 10μM can also promote the proliferation and maturation of dendritic cells.

Claims

1. CaMKII binding domain self-assembled protein nanoparticles, It is characterized in that The protein nanoparticles are formed by self-assembly of recombinant protein monomers in a buffer solution, and the amino acid sequence of the recombinant protein monomers at least includes the sequence shown in SEQ ID NO.

1.

2. The CaMKII binding domain self-assembled protein nanoparticles according to claim 1, It is characterized in that The amino acid sequence of the recombinant protein monomer is shown in SEQ ID NO.

1.

3. The CaMKII binding domain self-assembled protein nanoparticles according to claim 1, It is characterized in that The protein nanoparticles are 2-12mers of recombinant protein monomers, and the buffer is a neutral Tris buffer.

4. A method for preparing CaMKII binding domain self-assembled protein nanoparticles according to any one of claims 1 to 3, It is characterized in that The steps include: (1) constructing an expression vector containing a recombinant protein monomer gene; (2) transforming the expression vector into engineered bacteria to construct recombinant bacteria; (3) Cultivating recombinant bacteria to express recombinant protein monomers; (4) After the culture is completed, the bacteria are collected, broken into pieces, and then the protein is purified to obtain protein nanoparticles.

5. The method for preparing the CaMKII binding domain self-assembled protein nanoparticles according to claim 4, It is characterized in that In step (1), the gene sequence of the recombinant protein monomer is as shown in SEQ ID NO.2; and the expression vector is a recombinant plasmid.

6. The method for preparing the CaMKII binding domain self-assembled protein nanoparticles according to claim 4, It is characterized in that In step (2), the transformation method is as follows: the expression vector solution and the engineered bacterial suspension are mixed and then placed in an ice water bath for 2-8 minutes, then treated at 41-43°C for 25-35 seconds, and then placed in an ice water bath for 1.5-2.5 minutes, and then the bacterial solution is spread on the surface of a solid culture medium containing antibiotics. After cultivation, a positive single colony is picked out, which is the recombinant bacterium.

7. The method for preparing the CaMKII binding domain self-assembled protein nanoparticles according to claim 4, It is characterized in that In step (3), the method for culturing the recombinant bacteria is: inoculating the recombinant bacteria into LB liquid culture medium, and culturing the bacteria at 37° C. for 12-26 hours, during which time, inducing expression at 2-6 hours.

8. The method for preparing the CaMKII binding domain self-assembled protein nanoparticles according to claim 4, It is characterized in that In step (4), the method of purifying the protein after breaking the bacteria is as follows: resuspending the bacteria and then breaking the bacteria, collecting the supernatant by centrifugation, and purifying the supernatant using a nickel column and a chromatography column, wherein both the resuspending of the bacteria and the chromatography column purification use a neutral Tris buffer. 9 . Use of the CaMKII binding domain self-assembled protein nanoparticles according to any one of claims 1 to 3 in the preparation of an adjuvant or anti-tumor drug for enhancing tumor immunotherapy.

10. The use according to claim 9, It is characterized in that The tumor includes one or more of melanoma, breast cancer, cervical cancer, colorectal cancer, gastric cancer, lung cancer, liver cancer, esophageal cancer, pancreatic cancer, brain cancer, blood cancer, lymphoma, and bile duct cancer.